– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a ...
Mineralys Therapeutics is investing heavily in R&D for its lead candidate, lorundrostat, a treatment for hypertension and chronic kidney disease. R&D expenses nearly doubled from Q1 2022 to Q1 2023.
Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...
These tumors, known as adenomas, produce a hormone called aldosterone that raises blood pressure and can cause other cardiovascular problems. Adrenal tumors include nonfunctional adenomas (NFAs), ...
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – ...
Single-nucleus RNA sequencing of 2 nonfunctional adenomas and 3 aldosterone-producing adenomas revealed 13 clusters (Upper). Pseudotime course analysis predicted the transition of two cell fates in ...
The George Institute for Global Health is thrilled to congratulate doctoral researcher Dr Lauren Heath on receiving a ...
Hypertension affects one in three adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone dysregulation, often driven by obesity and primary aldosteronism, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results